Skip to main content
Pankit Vachhani, MD, Oncology, Birmingham, AL

PankitJaysukhVachhaniMD

Oncology • Birmingham, AL

Hematologic Oncology

Physician

Request Appointment

Overview of Dr. Vachhani

Dr. Pankit Vachhani is an oncologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including University of Alabama Hospital, USA Health University Hospital, and Russell Medical. He received his medical degree from Weill Cornell Medical College in Qatar and has been in practice 5 years. He is one of 74 doctors at University of Alabama Hospital and one of 39 doctors at USA Health University Hospital who specialize in Oncology. He has more than 60 publications and over 500 citings.

Education & Training

  • University at Buffalo
    University at BuffaloFellowship, Hematology and Medical Oncology, 2018
  • Virginia Commonwealth University Health System
    Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2012 - 2015
  • Weill Cornell Medical College in Qatar
    Weill Cornell Medical College in QatarClass of 2012

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2018 - 2025
  • VA State Medical License
    VA State Medical License 2012 - 2015
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience  
    Pankit Vachhani, Evelena P Ontiveros, Leukemia Research
  • Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience  
    Pankit Vachhani, Evelena P Ontiveros, Leukemia Research

Abstracts/Posters

  • Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant Abstract
    Pankit Vachhani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE¬ (Bispecific T-Cell Engager) in Patients with R...
    Pankit Vachhani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Quantification of Humoral Immune Response to Influenza Vaccination in MDS 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

  • Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center ExperienceOctober 2018

Press Mentions

  • Asymptomatic or Minimally Symptomatic Myelofibrosis
    Asymptomatic or Minimally Symptomatic MyelofibrosisNovember 4th, 2024
  • Systemic Mastocytosis: Information for Patients and Caregivers
    Systemic Mastocytosis: Information for Patients and CaregiversAugust 26th, 2024
  • Risk Stratification in Myelofibrosis: Which Model Should You Use?
    Risk Stratification in Myelofibrosis: Which Model Should You Use?July 3rd, 2024
  • Join now to see all

Dr. Pankit Vachhani, Dr. Pankit Vachhani, MD, Dr. P Vachhani, Dr. Pankit Jaysukh Vachhani